CFD and metabolic dysfunction-associated steatotic liver disease: As shown in Fig. 2, fasting blood glucose in NAFLD subjects decreased gradually with the increase of circulating adipsin (p = 0.001), however, there was no significant difference in non-NAFLD groups (p = 0.793 for non-NAFLD; p = 0.024 for interaction).